

**From:** Vas, Message (Gen) <message.vas@novartis.com>  
**Sent:** Thursday, September 1, 2022 10:40 AM  
**To:** Mahajan, Vinay  
**Subject:** ECN leadership announcement

---



## ECN leadership announcement

---

Dear colleagues,

I'm writing to share that Jay Bradner, M.D., will step down from the Executive Committee of Novartis (ECN) on October 31, 2022, and that Fiona Marshall, Ph.D., has been appointed the next President of the Novartis Institutes for BioMedical Research (NIBR).

I want to start by thanking Jay for his invaluable contributions to our company during his seven years leading research. Under his leadership, we have reimaged how we discover innovative medicines, recruited world-class scientific leaders, and expanded our collaborations with leading biotech companies and academic institutions. As lasting as his impact on our research efforts will be his legacy of leadership and inspiration. He has made a meaningful difference for associates within and outside of NIBR, and his deep love of and belief in the power of science have truly inspired us all. He has been a trusted thought partner on science topics, and I wish him the very best as he pursues his next chapter of scientific contribution and leadership outside of Novartis.

I'm grateful Jay has agreed to push out his departure and to help with the transition.

On November 1, 2022, we will welcome Dr. Fiona Marshall to Novartis—a leader who will help build on our strong NIBR foundations to shape our next era of biomedical research and innovation.

Fiona is an esteemed biomedical scientist and an accomplished biopharmaceuticals research leader. She will join us from MSD, known as Merck in the US, where she serves as Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine. Together with her collaborative leadership style and drive for performance, her three decades of experience leading drug discovery and early development across large biopharma, biotech, and academia and her deep passion for biomedical science make her the ideal leader to help us strengthen our innovation pipeline and advance future waves of high-value medicines. I look forward to collaborating with her on the ECN and on advancing our research agenda. You can learn more about Fiona [here](#).

As we look toward the future together, through changes that I know can be challenging, I hope you share my sense of optimism in all that we're aspiring to accomplish together, including flawless R&D, operational, and commercial execution to help us find and deliver our next era of life-changing medicines. As a pure-play innovative medicines company with more focus than ever, and with an executive leadership team energized to deliver on our ambitions, I am as confident as ever in our company and our future growth and success.

Thank you for your ongoing commitment as we shape a new, more focused, more innovative Novartis. Through reimagining ourselves and our company, we are gearing up to reimagine medicine in extraordinary ways and have an even greater impact on human health for decades to come.

Vas

*Read today's media and investor release [here](#).*

---

For internal use only and not to be shown, distributed or disseminated outside of Novartis.

